Ultragenyx Pharmaceutical Inc. financial data

Symbol
RARE on Nasdaq
Industry
Pharmaceutical Preparations
Location
60 Leveroni Court, Novato, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 19, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 277 % -1.41%
Quick Ratio 14.3 % +18.3%
Debt-to-equity 407 % -44%
Return On Equity -194 % +47.6%
Return On Assets -38.2 % +14.7%
Operating Margin -95.7 % +27%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 92.5M shares
Common Stock, Shares, Outstanding 92.5M shares +12.4%
Entity Public Float 3.7B USD +19.4%
Common Stock, Value, Issued 92K USD +12.2%
Weighted Average Number of Shares Outstanding, Basic 90.5M shares +23.1%
Weighted Average Number of Shares Outstanding, Diluted 90.5M shares +23.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 560M USD +29%
Research and Development Expense 698M USD +7.62%
Operating Income (Loss) -536M USD +5.84%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -568M USD +6.72%
Income Tax Expense (Benefit) 1.6M USD +99.5%
Net Income (Loss) Attributable to Parent -569M USD +6.17%
Earnings Per Share, Basic -6.29 USD/shares +23.8%
Earnings Per Share, Diluted -6.29 USD/shares +23.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 174M USD -18.7%
Accounts Receivable, after Allowance for Credit Loss, Current 122M USD +66%
Inventory, Net 45M USD +32.5%
Other Assets, Current 41.4M USD
Assets, Current 817M USD +11.6%
Property, Plant and Equipment, Net 266M USD -8.48%
Operating Lease, Right-of-Use Asset 25.5M USD +6.7%
Intangible Assets, Net (Excluding Goodwill) 178M USD +7.24%
Goodwill 44.4M USD 0%
Other Assets, Noncurrent 62.7M USD +8.66%
Assets 1.5B USD +0.84%
Accounts Payable, Current 38.8M USD -7.97%
Employee-related Liabilities, Current 94M USD +13.4%
Accrued Liabilities, Current 241M USD +22.6%
Liabilities, Current 344M USD +22.7%
Deferred Income Tax Liabilities, Net 30.1M USD 0%
Operating Lease, Liability, Noncurrent 30M USD -1.74%
Other Liabilities, Noncurrent 17.1M USD +40%
Liabilities 1.24B USD +2.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -643K USD -199%
Retained Earnings (Accumulated Deficit) -3.96B USD -16.8%
Stockholders' Equity Attributable to Parent 255M USD -7.3%
Liabilities and Equity 1.5B USD +0.84%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -191M USD -21.6%
Net Cash Provided by (Used in) Financing Activities -722K USD -145%
Net Cash Provided by (Used in) Investing Activities 94.4M USD -15.2%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 72.2M shares +2.99%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -97M USD -111%
Deferred Tax Assets, Valuation Allowance 1.21B USD +16.5%
Deferred Tax Assets, Gross 1.21B USD +16.5%
Operating Lease, Liability 40.3M USD -6.56%
Payments to Acquire Property, Plant, and Equipment 3.21M USD -87.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -570M USD +4.83%
Lessee, Operating Lease, Liability, to be Paid 49.6M USD -8.82%
Property, Plant and Equipment, Gross 378M USD +1.19%
Operating Lease, Liability, Current 10.3M USD -18.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 13.9M USD +16.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 13.8M USD -14.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +10.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.23M USD -17.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 9.02M USD +6.99%
Deferred Tax Assets, Operating Loss Carryforwards 309M USD +16.2%
Preferred Stock, Shares Authorized 25M shares 0%
Unrecognized Tax Benefits 97M USD +21.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 6.71M USD +14.4%
Additional Paid in Capital 4.21B USD +15%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 8.85M USD +68.9%
Deferred Tax Assets, Net of Valuation Allowance 7.15M USD +20%
Share-based Payment Arrangement, Expense 158M USD +16.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%